<DOC>
	<DOCNO>NCT02414022</DOCNO>
	<brief_summary>The plan analysis prospective cost-effectiveness ( cost-utility ) analysis perspective Canadian public healthcare system , examine cost outcomes ( quality-adjusted life year gain ) ibrutinib-based therapy compare standard therapy ( bendamutine-rituximab ) . Collection management data require economic analysis ( include resource utilization outcome ) fully integrated clinical data . Health state utility derive directly study population .</brief_summary>
	<brief_title>Economic Analysis Alliance A041202 CLL Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Patient must eligible core CLC.2/A041202 protocol . Patient consent must appropriately obtain accordance applicable local regulatory requirement . Each patient must sign consent form prior enrollment trial document willingness participate . Patient must able ( i.e . sufficiently fluent ) , willing complete health utility questionnaire English French . The baseline assessment must complete within require timeline , prior registration/randomization Inability ( illiteracy English French , loss sight , equivalent reason ) complete questionnaire make patient ineligible core protocol . However , ability unwillingness complete questionnaire make patient ineligible core protocol . Patients must accessible treatment followup . Investigators must assure patient randomized trial available complete documentation treatment , adverse event , followup .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>